Molecular basis for targeted therapy in T-cell lymphoma/leukemia.

T-cell lymphoma (TCL) is a collection of aggressive disorders with unfavorable outcome, where the introduction of targeted treatment is still in a preliminary phase. To gain deeper insights into deregulated mechanisms promoting this disease, we analyzed a panel of 34 representative T-cell lymphoma cells looking for predictive markers of response to targeted therapy. To do so, a combination of targeted sequencing was performed alongside with the expression of specific biomarkers corresponding to potentially activated survival pathways.